Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Trius Therapeutics' investigational drug Torezolid phosphate (TR-701) has received Patent number 7,816,379, entitled 'Oxazolidinone Derivatives' from the US Patent and Trademark Office (USPTO).
Subscribe to our email newsletter
Trius said that Torezolid phosphate (TR-701) is currently in Phase 3 clinical testing in patients with acute bacterial skin and skin structure infections (ABSSSI).
Trius has licensed patents in Australia, New Zealand and India, and a patent application in Russia where a notice of allowance was recently issued.
Trius president and CEO Jeffrey Stein said that the issuance of this patent adds to their intellectual property portfolio for Torezolid phosphate, an oxazolidinone in Phase 3 development.
Trius acquired worldwide rights outside of North and South Korea to a family of patent applications that provide patent coverage for composition of matter and methods of making and using Torezolid phosphate through an exclusive license from Dong-A Pharmaceuticals in 2007.
Trius has additionally filed patent applications directed to other aspects of Torezolid phosphate discovered by Trius’ scientists.